Last reviewed · How we verify
Rocuronium and Sugammadex
Rocuronium and Sugammadex, marketed by Herlev Hospital, is a neuromuscular blocking agent and its reversal agent that holds a significant position in the anesthesiology market. The key strength lies in the unique mechanism of action of Sugammadex, which rapidly reverses the effects of rocuronium, providing a competitive advantage in surgical procedures. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Rocuronium and Sugammadex |
|---|---|
| Sponsor | Herlev Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex
- Cardiac Output and Recovery Time (NA)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- Methylprednisolone vs Dexamethasone Interaction With Sugammadex in Pediatric Patients (NA)
- Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium and Sugammadex CI brief — competitive landscape report
- Rocuronium and Sugammadex updates RSS · CI watch RSS
- Herlev Hospital portfolio CI